DGEN — Deltagen Share Price
Last trade - 00:00- $0.00m
- -$0.02m
- $0.77m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0 | ||
| Price to Tang. Book | 0 | ||
| Price to Free Cashflow | 0 | ||
| Price to Sales | 0 | ||
| EV to EBITDA | -0.15 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 9.34% | ||
| Return on Equity | 9.54% | ||
| Operating Margin | 17.93% | ||
Financial Summary
| Year End 31st Dec | Unit | 2011 | 2012 | 2013 | 2014 | 2015 | 2016E | 2017E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.9 | 1.05 | 1.02 | 0.87 | 0.77 | n/a | n/a | -17.27% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Deltagen, Inc. is a provider of drug discovery tools and services to the biopharmaceutical industry. The Company offers a suite of programs designed to manage the efficiency of drug discovery, including access to biological models, as well as both small-molecule and secreted protein drug targets. In addition, it offers target validation data in the areas of immunology and metabolic diseases. The Company's biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Its DeltaBase is a searchable database of in vivo-derived mammalian gene function information and gene targets. DeltaOne from the Company provides per-gene access to the knockout mice and/or phenotypic data needed.
Directors
- Constantine Anagnostopoulos CHM (89)
- Larry Hill CEO
- Daniel Ratto CFO (54)
- Geoffrey Yarranton EVP (63)
- Donald Karanewsky SVP (63)
- Terry Coley VPR (41)
- John Burke GCN (44)
- Mark Moore TRS
- Peter Myers OTH (60)
- Augustine Yee SEC
- David Beier DRC (73)
- Thomas Penn DRC (63)
- William Scott DRC (75)
- Last Annual
- December 31st, 2015
- Last Interim
- December 31st, 2014
- Incorporated
- January 28th, 1997
- Public Since
- August 3rd, 2000
- No. of Employees
- 268
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 38,852,427
- Address
- 18 Iris Lane, Carlos, REDWOOD CITY, 94070
- Web
- Phone
- +1 6505695100
- Auditors
- Patel & Associates
Upcoming Events for DGEN
Similar to DGEN
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 20:12 UTC, shares in Deltagen are trading at $0.00. This share price information is delayed by 15 minutes.
Shares in Deltagen last closed at $0.00 and the price had moved by over the past 365 days. In terms of relative price strength the Deltagen share price has underperformed the S&P500 Index by -6.57% over the past year.
There is no consensus recommendation for this security.
Find out moreDeltagen does not currently pay a dividend.
Deltagen does not currently pay a dividend.
Deltagen does not currently pay a dividend.
To buy shares in Deltagen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.00, shares in Deltagen had a market capitalisation of $0.00m.
Here are the trading details for Deltagen:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: DGEN
Based on an overall assessment of its quality, value and momentum Deltagen is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Deltagen. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in Deltagen were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Deltagen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Deltagen's management team is headed by:
- Constantine Anagnostopoulos - CHM
- Larry Hill - CEO
- Daniel Ratto - CFO
- Geoffrey Yarranton - EVP
- Donald Karanewsky - SVP
- Terry Coley - VPR
- John Burke - GCN
- Mark Moore - TRS
- Peter Myers - OTH
- Augustine Yee - SEC
- David Beier - DRC
- Thomas Penn - DRC
- William Scott - DRC